Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00897624
Other study ID # CDR0000633500
Secondary ID CLCC-IC-Micromet
Status Completed
Phase N/A
First received May 9, 2009
Last updated May 12, 2011
Start date November 2007

Study information

Verified date May 2011
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

RATIONALE: Studying samples of bone marrow and blood from patients with cancer may help doctors find out the extent of disease.

PURPOSE: This research study is collecting bone marrow and blood samples from patients with metastatic choroid melanoma.


Description:

OBJECTIVES:

Primary

- Develop and validate a method of detecting tumor cells in the bone marrow and blood in patients with metastatic choroid melanoma.

OUTLINE: While patients are under general anesthesia for standard treatment of their disease, samples of bone marrow from the iliac crest and blood are collected. Samples are analyzed for the expression of tyrosinase and Melan-a via RT-PCR.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Choroid melanoma

- Metastatic disease

- Planning to undergo general anesthesia

PATIENT CHARACTERISTICS:

- Not pregnant or nursing

- No contraindications to the collection of a bone marrow sample

- No patient deprived of liberty or under trusteeship (including guardianship)

- No social or psychological situations that preclude the ability to give consent

PRIOR CONCURRENT THERAPY:

- Not specified

Study Design

N/A


Related Conditions & MeSH terms


Intervention

Genetic:
gene expression analysis

reverse transcriptase-polymerase chain reaction

Other:
laboratory biomarker analysis


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Institut Curie

Outcome

Type Measure Description Time frame Safety issue
Primary Detection of micro-metastatic cells in 20 x 10^6 nucleated cells No
See also
  Status Clinical Trial Phase
Recruiting NCT01217398 - Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Phase 2
Completed NCT00471471 - Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Phase 1
Completed NCT00398073 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma N/A
Completed NCT00334776 - Vaccine Therapy in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00025181 - Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery Phase 1
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00003339 - Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma Phase 2
Completed NCT00084656 - Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Phase 2
Completed NCT00705640 - Vaccine Therapy in Treating Patients With Advanced Melanoma Phase 1
Recruiting NCT00489944 - Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Phase 2
Completed NCT00027742 - Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Phase 2
Completed NCT00952939 - Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye N/A
Terminated NCT00005841 - Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Phase 1
Completed NCT00072345 - Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Phase 2
Completed NCT00089219 - Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Phase 1/Phase 2
Completed NCT00243061 - AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Phase 2
Completed NCT00445965 - Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase 2
Terminated NCT00110123 - Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Phase 3
Completed NCT00032045 - Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Phase 2
Completed NCT00238329 - PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Phase 2